Eledon reports Q4 2022 net loss of $58.4M, including $48.6M goodwill impairment; refocuses on kidney transplant

Eledon Pharmaceuticals, Inc.

Q4 2022 net loss $58.4M ($4.09/share) vs $8.8M ($0.59) in Q4 2021; full-year net loss $88.0M ($6.16) vs $34.5M ($2.33).
Cash and equivalents $56.4M at Dec 31, 2022; expected to fund operations into Q1 2024.
Phase 1b kidney transplant trial dosed fourth patient; data on first three to be presented at WCN March 31, 2023.
Deprioritized IgAN program and discontinued islet cell trial; collaboration with eGenesis for xenotransplantation.
Subject to financing, Phase 2 BESTOW trial of tegoprubart in kidney transplant expected to initiate mid-2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income net loss of $88.0 million, or $6.16 per share.

Period: the year ended December 31, 2022
Net income: net loss of $88.0 million, or $6.16 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $88.0 million, or $6.16 per share, for the year ended December 31, 2022, compared to a net loss of $34.5 million, or $2.33 per share, in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eledon Pharmaceuticals, Inc. reported the four months ended December 31, 2022 results: net income net loss of $58.4 million, or $4.09 per share.

Period: the four months ended December 31, 2022
Net income: net loss of $58.4 million, or $4.09 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $58.4 million, or $4.09 per share, for the three months ended December 31, 2022, compared to a net loss of $8.8 million, or $0.59 per share, for the same period in 2021.

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.